rs2236295 (ADO) and rs2307441 (POLG) were identified within the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD), and they were characterised as potential predictors of venlafaxine extended release (XR) treatment outcome. This evidence concerns the gene ADO and generalized anxiety disorder.